ATE256681T1 - N-heterozyklische derivate als nos inhibitoren - Google Patents

N-heterozyklische derivate als nos inhibitoren

Info

Publication number: ATE256681T1
Authority: AT; Austria
Prior art keywords: heterocyclic derivatives; nos inhibitors; inhibitors; compounds; nitric oxide
Prior art date: 1999-08-26

Application number

AT00959333T

Other languages

English (en)

Inventor

Damian O Arnaiz

John J Baldwin

David D Davey

James J Devlin

Roland Ellwood Dolle Iii

Shawn David Erickson

Kirk Mcmillan

Michael M Morrissey

Michael H J Ohlmeyer

Gonghua Pan

Vidyadhar Madhav Paradkar

John Parkinson

Gary B Phillips

Bin Ye

Zuchun Zhao

Original Assignee

Berlex Lab

Pharmacopeia Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-26

Filing date

2000-08-24

Publication date

2004-01-15

2000-08-24 Application filed by Berlex Lab, Pharmacopeia Inc filed Critical Berlex Lab

2004-01-15 Application granted granted Critical

2004-01-15 Publication of ATE256681T1 publication Critical patent/ATE256681T1/de

Links

239000003112 inhibitor Substances 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 2
108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002194 synthesizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Immunology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Psychology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT00959333T 1999-08-26 2000-08-24 N-heterozyklische derivate als nos inhibitoren ATE256681T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/383,813 US6432947B1 (en)	1997-02-19	1999-08-26	N-heterocyclic derivatives as NOS inhibitors
PCT/US2000/023173 WO2001014371A1 (en)	1999-08-26	2000-08-24	N-heterocyclic derivatives as nos inhibitors

Publications (1)

Publication Number	Publication Date
ATE256681T1 true ATE256681T1 (de)	2004-01-15

Family

ID=23514822

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00959333T ATE256681T1 (de)	1999-08-26	2000-08-24	N-heterozyklische derivate als nos inhibitoren

Country Status (34)

Country	Link
US (11)	US6432947B1 (de)
EP (1)	EP1206467B1 (de)
JP (1)	JP4739625B2 (de)
KR (1)	KR100708783B1 (de)
CN (1)	CN1206228C (de)
AT (1)	ATE256681T1 (de)
AU (1)	AU769405B2 (de)
BG (1)	BG65804B1 (de)
BR (1)	BR0014144A (de)
CA (1)	CA2376355C (de)
CZ (1)	CZ2002642A3 (de)
DE (1)	DE60007329T2 (de)
DK (1)	DK1206467T3 (de)
EE (1)	EE05199B1 (de)
ES (1)	ES2213599T3 (de)
HK (1)	HK1043594A1 (de)
HR (1)	HRP20020175B1 (de)
HU (1)	HUP0202450A3 (de)
IL (2)	IL148313A0 (de)
LT (1)	LT4982B (de)
LV (1)	LV12887B (de)
MX (1)	MXPA02002022A (de)
NO (1)	NO323886B1 (de)
NZ (1)	NZ517411A (de)
PL (1)	PL353539A1 (de)
PT (1)	PT1206467E (de)
RO (1)	RO122202B1 (de)
RS (1)	RS50378B (de)
RU (1)	RU2277094C2 (de)
SI (1)	SI20818B (de)
SK (1)	SK2622002A3 (de)
UA (1)	UA72930C2 (de)
WO (1)	WO2001014371A1 (de)
ZA (1)	ZA200201485B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6432947B1 (en) *	1997-02-19	2002-08-13	Berlex Laboratories, Inc.	N-heterocyclic derivatives as NOS inhibitors
HRP990246A2 (en) *	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en)	1998-08-07	2004-09-24	Pont Pharmaceuticals Du	Succinoylamino lactams as inhibitors of Abeta protein production
ATE250053T1 (de) *	1999-07-15	2003-10-15	Pharmacopeia Inc	Bradikinin b1 rezeptor antagonisten
GB2361473C (en) *	2000-03-08	2005-06-28	Microgenics Corp	Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
CN1436175A (zh)	2000-04-03	2003-08-13	布里斯托尔-迈尔斯斯奎布药品公司	作为Aβ－蛋白生产抑制剂的环状内酰胺
US20030055249A1 (en) *	2001-07-17	2003-03-20	Fick David B.	Synthesis and methods of use of pyrimidine analogues and derivatives
US8571653B2 (en) *	2001-08-31	2013-10-29	Bio Control Medical (B.C.M.) Ltd.	Nerve stimulation techniques
US7885709B2 (en) *	2001-08-31	2011-02-08	Bio Control Medical (B.C.M.) Ltd.	Nerve stimulation for treating disorders
US7778711B2 (en) *	2001-08-31	2010-08-17	Bio Control Medical (B.C.M.) Ltd.	Reduction of heart rate variability by parasympathetic stimulation
US7904176B2 (en)	2006-09-07	2011-03-08	Bio Control Medical (B.C.M.) Ltd.	Techniques for reducing pain associated with nerve stimulation
US6982259B2 (en) *	2002-04-30	2006-01-03	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors
EP1795192A3 (de) *	2002-04-30	2008-05-07	Bayer Schering Pharma Aktiengesellschaft	1-(pyridazin-3-yl)-Imidazol Derivaten als NO-Synthase (NOS) Hemmer
AU2003260033A1 (en) *	2002-08-29	2004-03-19	Schering Aktiengesellschaft	Methods of treating acute respiratory distress syndrome
AU2003267728A1 (en) *	2002-10-18	2004-05-04	Pfizer Products Inc.	Cannabinoid receptor ligands and uses thereof
CA2555073A1 (en) *	2004-02-12	2005-09-01	Merck & Co., Inc.	Amino heterocyclic modulators of chemokine receptor activity
EP1568698A1 (de) *	2004-02-27	2005-08-31	Aventis Pharma Deutschland GmbH	Pyrrolderivate als faktor-xa-inhibitoren
KR100935273B1 (ko) *	2004-06-10	2010-01-06	아이알엠 엘엘씨	단백질 키나제 억제제 화합물 및 조성물
JP4688876B2 (ja) *	2004-06-10	2011-05-25	アイアールエム・リミテッド・ライアビリティ・カンパニー	タンパク質キナーゼ阻害剤としての化合物および組成物
US7820654B2 (en) *	2004-09-23	2010-10-26	Dr. Reddy's Laboratories Ltd.	Pyrimidine compounds, process for their preparation and compositions containing them
UY29177A1 (es) *	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) *	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP2008520713A (ja) *	2004-11-17	2008-06-19	ミイカナセラピューティクスインコーポレイテッド	キナーゼ阻害剤
AR055287A1 (es) *	2004-12-01	2007-08-15	Kalypsys Inc	Inhibidores de la dimerizacion de la sintasa inducible por oxido nitrico ,composiciones farmaceuticas
US20070123572A1 (en) *	2005-11-28	2007-05-31	Kalypsys, Inc.	Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines
KR101155335B1 (ko) *	2005-01-07	2012-06-11	엘지전자 주식회사	이동통신 단말기의 멀티미디어 메시지 동작방법
US7884109B2 (en) *	2005-04-05	2011-02-08	Wyeth Llc	Purine and imidazopyridine derivatives for immunosuppression
NZ562468A (en) *	2005-04-05	2009-10-30	Pharmacopeia Inc	Purine and imidazopyridine derivatives for immunosuppression
WO2007020888A1 (ja)	2005-08-12	2007-02-22	Takeda Pharmaceutical Company Limited	脳・神経細胞保護剤および睡眠障害治療薬
CA2622352C (en) *	2005-09-30	2014-05-27	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
BRPI0620526A2 (pt) *	2005-11-28	2011-11-16	Kalypsys Inc	sal de acetato e método para alcançar um efeito em um paciente
US20090281075A1 (en) *	2006-02-17	2009-11-12	Pharmacopeia, Inc.	Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7989459B2 (en) *	2006-02-17	2011-08-02	Pharmacopeia, Llc	Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US8017612B2 (en) *	2006-04-18	2011-09-13	Japan Tobacco Inc.	Piperazine compound and use thereof as a HCV polymerase inhibitor
JP2009534454A (ja) *	2006-04-25	2009-09-24	アステックス、セラピューティックス、リミテッド	医薬化合物
WO2007125321A2 (en) *	2006-04-25	2007-11-08	Astex Therapeutics Limited	Purine and deazapurine derivatives as pharmaceutical compounds
PL2066791T3 (pl)	2006-10-03	2013-02-28	Genzyme Corp	Terapia Genowa do leczenia stwardnienia zanikowego bocznego i innych zaburzeń rdzenia kręgowego
TW200831104A (en) *	2006-10-04	2008-08-01	Pharmacopeia Inc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200837064A (en) *	2006-10-04	2008-09-16	Pharmacopeia Inc	8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US7902187B2 (en) *	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20080119496A1 (en) *	2006-11-16	2008-05-22	Pharmacopeia Drug Discovery, Inc.	7-Substituted Purine Derivatives for Immunosuppression
EP1939181A1 (de) *	2006-12-27	2008-07-02	sanofi-aventis	Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression
AU2008262291A1 (en) *	2007-06-11	2008-12-18	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
PL2201012T3 (pl)	2007-10-11	2014-11-28	Astrazeneca Ab	Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
WO2009097476A1 (en) *	2008-01-30	2009-08-06	Smithkline Beecham Corporation	NOVEL sEH INHIBITORS AND THEIR USE
WO2009097474A1 (en) *	2008-01-30	2009-08-06	Smithkline Beecham Corporation	Novel seh inhibitors and their use
EP2240025A4 (de) *	2008-01-30	2012-03-28	Glaxosmithkline Llc	Neue seh-hemmer und ihre verwendung
EP2276750A2 (de) *	2008-03-27	2011-01-26	Auckland Uniservices Limited	Substituierte pyrimidine und triazine und deren verwendung in der krebstherapie
GB0908394D0 (en)	2009-05-15	2009-06-24	Univ Leuven Kath	Novel viral replication inhibitors
GB0913636D0 (en)	2009-08-05	2009-09-16	Univ Leuven Kath	Novel viral replication inhibitors
BR112012006130A2 (pt)	2009-09-18	2016-06-28	Volvo Lastvagnar Ab	console para atamento para um chassi de veículo e veículo compreendendo um console de transporte de suspensão.
JP2013542243A (ja)	2010-11-15	2013-11-21	カトリーケウニヴェルシテイトルーヴェン	新規な抗ウイルス性化合物
CN102617503B (zh) *	2011-03-03	2014-05-07	上海常丰生物医药科技有限公司	(s)-3-吗啉基羧酸的合成方法
EP2694056B1 (de)	2011-04-01	2019-10-16	AstraZeneca AB	Therapeutische behandlung
PH12014500943A1 (en)	2011-11-30	2014-06-30	Astrazeneca Ab	Combination treatment of cancer
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
WO2016007966A2 (en) *	2014-07-11	2016-01-14	Northwestern University	2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
GB201512635D0 (en)	2015-07-17	2015-08-26	Ucl Business Plc	Uses of therapeutic compounds
SMT202100225T1 (it)	2016-12-20	2021-05-07	Astrazeneca Ab	Composti di ammino-triazolopiridina e loro uso nel trattamento del cancro
CN107115334A (zh) *	2017-03-04	2017-09-01	王宏	一种治疗免疫性流产的药物组合物
WO2019183577A1 (en)	2018-03-23	2019-09-26	Carmot Therapeutics, Inc.	Modulators of g-protein coupled receptors
EP3628669A1 (de)	2018-09-28	2020-04-01	GenKyoTex Suisse SA	Neuartige verbindungen als nadph-oxidase-inhibitoren
IL308392A (en)	2021-05-13	2024-01-01	Carmot Therapeutics Inc	G protein-coupled receptor modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6339875A (ja)	1986-08-05	1988-02-20	Nissin Food Prod Co Ltd	ピリミジン誘導体
DE4118720A1 (de)	1991-06-07	1992-12-10	Bayer Ag	Substituierte imidazolinylpyrimidine
EP0548553A1 (de) *	1991-11-25	1993-06-30	Takeda Chemical Industries, Ltd.	Optisch aktive Azolverbindungen, ihre Herstellung und Anwendung
CA2131004A1 (en) *	1992-02-28	1993-09-02	Hideshi Kobayashi	S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component
TW279864B (de) *	1993-02-19	1996-07-01	Janssen Pharmaceutica Nv
US5593992A (en)	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
EP0640599B1 (de)	1993-08-26	1998-03-04	Ono Pharmaceutical Co., Ltd.	4-Aminopyrimidin Derivate
US5426110A (en)	1993-10-06	1995-06-20	Eli Lilly And Company	Pyrimidinyl-glutamic acid derivatives
US5629322A (en)	1994-11-15	1997-05-13	Merck & Co., Inc.	Cyclic amidine analogs as inhibitors of nitric oxide synthase
WO1996014842A1 (en)	1994-11-15	1996-05-23	Merck & Co., Inc.	Substituted heterocycles as inhibitors of nitric oxide synthase
BR9611157A (pt) *	1995-11-01	1999-03-30	Novartis Ag	Derivados de purina e processos para sua preparação
ZA977427B (en)	1996-09-04	1998-03-02	Dainippon Pharmaceutical Co	2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same.
PL335235A1 (en) *	1997-02-19	2000-04-10	Berlex Lab	N-heterocyclic derivatives as nos inhibitors
US6432947B1 (en) *	1997-02-19	2002-08-13	Berlex Laboratories, Inc.	N-heterocyclic derivatives as NOS inhibitors
US6172005B1 (en) *	1997-03-11	2001-01-09	E. I. Du Pont De Nemours And Company	Heteroaryl azole herbicides
US6525051B2 (en)	2000-03-27	2003-02-25	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors

1999
- 1999-08-26 US US09/383,813 patent/US6432947B1/en not_active Expired - Fee Related
2000
- 2000-08-24 KR KR1020027002407A patent/KR100708783B1/ko not_active Expired - Fee Related
- 2000-08-24 RO ROA200200205A patent/RO122202B1/ro unknown
- 2000-08-24 HK HK02105317.3A patent/HK1043594A1/zh unknown
- 2000-08-24 DK DK00959333T patent/DK1206467T3/da active
- 2000-08-24 CZ CZ2002642A patent/CZ2002642A3/cs unknown
- 2000-08-24 AU AU70671/00A patent/AU769405B2/en not_active Ceased
- 2000-08-24 CN CNB008146691A patent/CN1206228C/zh not_active Expired - Fee Related
- 2000-08-24 NZ NZ517411A patent/NZ517411A/en unknown
- 2000-08-24 EE EEP200200091A patent/EE05199B1/xx not_active IP Right Cessation
- 2000-08-24 PT PT00959333T patent/PT1206467E/pt unknown
- 2000-08-24 EP EP00959333A patent/EP1206467B1/de not_active Expired - Lifetime
- 2000-08-24 IL IL14831300A patent/IL148313A0/xx active IP Right Grant
- 2000-08-24 RU RU2002107203/04A patent/RU2277094C2/ru not_active IP Right Cessation
- 2000-08-24 DE DE60007329T patent/DE60007329T2/de not_active Expired - Lifetime
- 2000-08-24 MX MXPA02002022A patent/MXPA02002022A/es active IP Right Grant
- 2000-08-24 PL PL00353539A patent/PL353539A1/xx not_active Application Discontinuation
- 2000-08-24 ES ES00959333T patent/ES2213599T3/es not_active Expired - Lifetime
- 2000-08-24 CA CA002376355A patent/CA2376355C/en not_active Expired - Fee Related
- 2000-08-24 AT AT00959333T patent/ATE256681T1/de not_active IP Right Cessation
- 2000-08-24 SK SK262-2002A patent/SK2622002A3/sk unknown
- 2000-08-24 HR HR20020175A patent/HRP20020175B1/xx not_active IP Right Cessation
- 2000-08-24 BR BR0014144-5A patent/BR0014144A/pt not_active Application Discontinuation
- 2000-08-24 HU HU0202450A patent/HUP0202450A3/hu unknown
- 2000-08-24 RS YUP-120/02A patent/RS50378B/sr unknown
- 2000-08-24 WO PCT/US2000/023173 patent/WO2001014371A1/en not_active Ceased
- 2000-08-24 SI SI200020040A patent/SI20818B/sl not_active IP Right Cessation
- 2000-08-24 JP JP2001518702A patent/JP4739625B2/ja not_active Expired - Fee Related
- 2000-08-24 UA UA2002032401A patent/UA72930C2/uk unknown
2002
- 2002-02-21 IL IL148313A patent/IL148313A/en not_active IP Right Cessation
- 2002-02-21 ZA ZA200201485A patent/ZA200201485B/en unknown
- 2002-02-26 BG BG106440A patent/BG65804B1/bg unknown
- 2002-02-26 NO NO20020925A patent/NO323886B1/no not_active IP Right Cessation
- 2002-03-15 LT LT2002028A patent/LT4982B/lt not_active IP Right Cessation
- 2002-03-26 LV LVP-02-50A patent/LV12887B/en unknown
- 2002-04-12 US US10/121,212 patent/US6849739B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/122,047 patent/US6887865B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,886 patent/US6841673B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,758 patent/US6846829B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,379 patent/US6747031B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,808 patent/US6670473B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,682 patent/US20030073669A1/en not_active Abandoned
- 2002-04-12 US US10/122,006 patent/US6864368B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,659 patent/US6864263B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/122,072 patent/US6841674B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HUP0202450A2 (hu)	2002-11-28
EE200200091A (et)	2003-04-15
US20030078265A1 (en)	2003-04-24
RO122202B1 (ro)	2009-02-27
BR0014144A (pt)	2002-05-21
US20030073669A1 (en)	2003-04-17
US20030060452A1 (en)	2003-03-27
EP1206467B1 (de)	2003-12-17
US20030027794A1 (en)	2003-02-06
KR20020062277A (ko)	2002-07-25
NO20020925D0 (no)	2002-02-26
BG65804B1 (bg)	2009-12-31
CN1382136A (zh)	2002-11-27
BG106440A (en)	2002-11-29
AU7067100A (en)	2001-03-19
NO323886B1 (no)	2007-07-16
DE60007329D1 (de)	2004-01-29
YU12002A (sh)	2005-03-15
EP1206467A1 (de)	2002-05-22
SI20818A (sl)	2002-08-31
CN1206228C (zh)	2005-06-15
US20030083332A1 (en)	2003-05-01
AU769405B2 (en)	2004-01-29
US6849739B2 (en)	2005-02-01
RS50378B (sr)	2009-11-10
ES2213599T3 (es)	2004-09-01
PL353539A1 (en)	2003-12-01
PT1206467E (pt)	2004-05-31
SK2622002A3 (en)	2002-09-10
DK1206467T3 (da)	2004-04-26
UA72930C2 (uk)	2005-05-16
LT4982B (lt)	2003-01-27
HRP20020175B1 (hr)	2008-07-31
US6864263B2 (en)	2005-03-08
US6432947B1 (en)	2002-08-13
IL148313A (en)	2008-04-13
US6841673B2 (en)	2005-01-11
ZA200201485B (en)	2003-07-30
SI20818B (sl)	2009-04-30
US20020165203A1 (en)	2002-11-07
HK1043594A1 (zh)	2002-09-20
NO20020925L (no)	2002-04-16
CA2376355C (en)	2009-10-27
IL148313A0 (en)	2002-09-12
HK1051683A1 (en)	2003-08-15
KR100708783B1 (ko)	2007-04-19
HRP20020175A2 (en)	2005-10-31
JP2003507476A (ja)	2003-02-25
US20020183323A1 (en)	2002-12-05
US20030004137A1 (en)	2003-01-02
US6747031B2 (en)	2004-06-08
CZ2002642A3 (cs)	2002-08-14
CA2376355A1 (en)	2001-03-01
JP4739625B2 (ja)	2011-08-03
EE05199B1 (et)	2009-08-17
US20030069210A1 (en)	2003-04-10
WO2001014371A1 (en)	2001-03-01
US6841674B2 (en)	2005-01-11
HUP0202450A3 (en)	2003-12-29
US6846829B2 (en)	2005-01-25
US6670473B2 (en)	2003-12-30
RU2277094C2 (ru)	2006-05-27
US6864368B2 (en)	2005-03-08
LV12887B (en)	2003-01-20
US6887865B2 (en)	2005-05-03
US20030092678A1 (en)	2003-05-15
NZ517411A (en)	2003-09-26
LT2002028A (en)	2002-09-25
MXPA02002022A (es)	2002-10-31
DE60007329T2 (de)	2004-06-09

Legal Events

Date

Code

Title

Description

2004-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1206467

Country of ref document: EP

2011-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE256681T1 (de)	2004-01-15	N-heterozyklische derivate als nos inhibitoren
ATE345339T1 (de)	2006-12-15	N-heterocyclische derivate als nos inhibitoren
DE60101000D1 (de)	2003-11-20	N-heterocyclische derivate als nos inhibitoren
DE60311646D1 (de)	2007-03-22	1-substituierten imidazol derivaten als nos inhibitoren
ATE498600T1 (de)	2011-03-15	Inden derivate als pharmazeutika
ATE419242T1 (de)	2009-01-15	Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60222465D1 (de)	2007-10-25	Pyrazolopyridin-derivate als antiherpesmittel
ATE274515T1 (de)	2004-09-15	Pyrazolopyridinderivate
SE9904128D0 (sv)	1999-11-15	Novel compounds